Once-daily tiotropium Respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
O Schmidt, D Halpin, E Bateman, P Paggiaro, E Bleecker, M Engel, P Moroni-Zentgraf, H Schmidt, H Kerstjens · Pneumologie · 2015 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: A reduction in asthma exacerbation risk may provide improvements in clinical burden, patient experience and healthcare costs. In Phase III trials, once-daily tiotropium Respimat (tioR) add-on to at least ICS improved lung function in symptomatic asthma patients. We investigated exacerbation risk in each trial. Methods: Five Phase III double-blind, placebo-controlled, parallel-group trials in patients with symptomatic asthma. Patients received tioR 5 µg or placebo Respimat (pboR) as add-on to at least ICS maintenance therapy (200 – > 800 µg budesonide or equivalent). Pre-planned co-primary or secondar…
